Late last year we filed a patent on the synergistic inhibition of glioma using pterostilbene. Our data suggest that when pterostilbene is combined with brain cancer therapeutics such as Temozolomide, Sertraline, or Gefitinib, their prognosis is improved. Furthermore, we observed that pterostilbene causes an increase of immunogenicity in chemotherapy-treated cancer cells, providing heightened immunity to cancer cells that escaped chemotherapy, theoretically enhancing patient prognosis
We are working on integrating NeuroStilbene into various protocols that are currently in development in order to enhance therapeutic options to patients with dreaded conditions such as brain tumors and neurodegenerative diseases
The optimized formulation developed, possesses an enhanced delivery ability and increased concentration of the active ingredient, pterostilbene
The new formulation utilizes nanoparticle technology, combined with proprietary chemistry to ensure optimal concentrations of the active agent are found in the central nervous system to prevent pathology associated with neuronal injury